8-K: Biogen Reports Mixed Q1 2024 Results: EPS Growth Amidst Revenue Decline

Biogen's first quarter of 2024 saw a 1% increase in GAAP EPS and an 8% increase in non-GAAP EPS, despite a 7% decrease in total revenue.

Summary

• Biogen reported its first quarter 2024 financial results, showing a mixed performance.
• Total revenue decreased by 7% to $2.3 billion compared to the same period last year.
• Product revenue declined by 3%, while contract manufacturing, royalty, and other revenue saw a significant decrease of 39%.
• However, GAAP diluted EPS grew by 1% to $2.70, and non-GAAP diluted EPS increased by 8% to $3.67.
• The company experienced a 10% growth in GAAP operating income and a 24% growth in non-GAAP operating income.
• LEQEMBI launch uptake accelerated with first quarter global in-market sales of approximately $19 million, nearly triple the fourth quarter of 2023.
• SKYCLARYS generated $78 million in global revenue, with patient identification and access progressing in the U.S. and E.U.
• Biogen reaffirmed its full-year 2024 financial guidance, expecting non-GAAP EPS of $15.00 to $16.00, representing approximately 5% growth at the mid-point.
• The company anticipates total revenue to decline by a lowto mid-single digit percentage, but core pharmaceutical revenue to be flat compared to 2023.
• Operating income is expected to grow by a low-double digit percentage, with a mid-single digit percentage point operating margin improvement.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the EPS growth and progress in new product launches, but tempered by the revenue decline and ongoing challenges. The reaffirmation of guidance provides some stability, but the mixed results prevent a higher score.

Positives

• The company achieved growth in both GAAP and non-GAAP earnings per share.
• LEQEMBI's launch is showing strong momentum with a significant increase in sales and new patient starts.
• SKYCLARYS is performing well with successful launches in the U.S. and E.U.
• The 'Fit for Growth' program is delivering substantial cost savings and margin improvements.
• Biogen reaffirmed its full-year 2024 financial guidance, indicating confidence in future performance.
• The company has a strong free cash flow of $507 million for the quarter.
• There was a significant decrease in idle capacity charges compared to the first quarter of 2023.

Negatives

• Total revenue decreased by 7% compared to the first quarter of 2023.
• Product revenue declined by 3% year-over-year.
• Contract manufacturing, royalty, and other revenue experienced a substantial decrease of 39%.
• Multiple sclerosis product revenue decreased by 4%.
• Rare disease revenue also decreased by 4%.
• The company has a net debt of approximately $5.5 billion.

Risks

• The company is facing increased competition in some of its product areas.
• There is a risk of continued decline in multiple sclerosis product revenue.
• The company's financial guidance does not include potential impacts from acquisitions, large business development transactions, or litigation.
• The company's future performance is subject to various risks and uncertainties, including regulatory approvals, clinical trial outcomes, and market conditions.
• There are risks associated with the commercialization of biosimilars.

Future Outlook

Biogen reaffirmed its full-year 2024 financial guidance, expecting non-GAAP EPS of $15.00 to $16.00, representing approximately 5% growth at the mid-point. The company anticipates total revenue to decline by a lowto mid-single digit percentage, but core pharmaceutical revenue to be flat compared to 2023. Operating income is expected to grow by a low-double digit percentage, with a mid-single digit percentage point operating margin improvement.

Management Comments

• President and Chief Executive Officer Christopher A. Viehbacher stated that the company is starting 2024 with an increase in earnings per share and solid execution across new product launches.
• He noted the realization of meaningful cost savings and margin improvement.
• He expressed encouragement about the momentum building for LEQEMBI and the progress of SKYCLARYS in rare disease.
• He also highlighted the encouraging early trends for ZURZUVAE and QALSODY.
• He emphasized the company's renewed culture focused on purpose and performance, aiming for sustainable growth and enhanced value for patients and shareholders.

Industry Context

Biogen's results reflect the ongoing challenges and opportunities in the biotechnology sector, particularly in the areas of Alzheimer's disease, rare diseases, and multiple sclerosis. The company's focus on new product launches and cost management aligns with industry trends of seeking growth through innovation and efficiency. The performance of LEQEMBI is being closely watched as a key indicator of the potential for Alzheimer's treatments, and the success of SKYCLARYS highlights the importance of rare disease therapies.

Comparison to Industry Standards

• Biogen's 8% non-GAAP EPS growth is a positive sign, but the 7% revenue decline is a concern compared to some peers in the biotech industry that are experiencing revenue growth.
• The launch of LEQEMBI, with $19 million in sales, is a positive start but needs to be compared to other Alzheimer's treatments in the market to assess its long-term potential.
• SKYCLARYS's $78 million in revenue is a good result for a rare disease drug launch, but its long-term success will depend on patient access and market penetration.
• Companies like Vertex Pharmaceuticals, which focuses on rare diseases, have shown strong revenue growth, setting a high benchmark for Biogen's rare disease portfolio.
• The cost-cutting measures and margin improvements are in line with industry trends, where companies are focusing on operational efficiency to drive profitability.
• Biogen's debt of $5.5 billion is significant and needs to be monitored against industry averages and its ability to generate cash flow to service the debt.

Related Party Transactions

• First quarter 2024 GAAP and Non-GAAP collaboration profit sharing was a net expense of $66 million, which includes $61 million related to Biogen's collaboration with Samsung Bioepis, and $5 million to Sage Therapeutics related to the commercialization of ZURZUVAE in the U.S.

Stakeholder Impact

• Shareholders will be impacted by the mixed financial results, with positive EPS growth but a decline in revenue.
• Patients will benefit from the continued launch and availability of new therapies like LEQEMBI, SKYCLARYS, and ZURZUVAE.
• Employees may be affected by the ongoing 'Fit for Growth' program, which includes cost-saving initiatives.
• Suppliers and partners will be impacted by the company's overall financial performance and strategic direction.
• Creditors will be interested in the company's debt levels and ability to generate cash flow.

Next Steps

• Biogen will continue to focus on the launch and uptake of LEQEMBI, SKYCLARYS, and ZURZUVAE.
• The company will continue to execute its 'Fit for Growth' program to achieve cost savings and margin improvements.
• Biogen will monitor the performance of its multiple sclerosis portfolio and address competitive pressures.
• The company will provide further updates on its financial performance and strategic initiatives in future reports and conference calls.

Key Dates

Keywords

Biogen, BIIB, LEQEMBI, SKYCLARYS, ZURZUVAE, SPINRAZA, Earnings, Revenue, Pharmaceuticals, Biotechnology, Financial Results, EPS, Operating Income, Rare Disease, Multiple Sclerosis